Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Rituximab

Review the clinical trials studying rituximab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 123

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Status: Active
Location: 229 locations
Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Status: Active
Location: 225 locations
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Status: Active
Location: 101 locations
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Status: Active
Location: 47 locations
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Status: Active
Location: 32 locations
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Status: Active
Location: 19 locations
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Status: Active
Location: 16 locations
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Status: Active
Location: 14 locations
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Status: Active
Location: 14 locations
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Status: Active
Location: 12 locations
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Location: 11 locations
Pembrolizumab, Ibrutinib, and Rituximab for the Treatment of Relapse or Refractory Primary Central Nervous System Lymphoma
Status: Active
Location: 10 locations
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Status: Active
Location: 9 locations
Zanubrutinib in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and High-Dose Methotrexate for the Treatment of Patients with Large B-cell Lymphoma with Central Nervous System Involvement
Status: Active
Location: 8 locations
Glucarpidase in Treating Patients with Central Nervous System B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 8 locations
Enasidenib with or without Rituximab for the Treatment of Relapsed and Refractory IDH2-Mutant Angioimmunoblastic T-cell Lymphoma
Status: Active
Location: 7 locations
Golcadomide and Rituximab as Bridging Therapy for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma before CAR T-cell Therapy
Status: Active
Location: 7 locations
Vemurafenib and Obinutuzumab versus Standard Cladribine and Rituximab of the Treatment of Untreated Hairy Cell Leukemia
Status: Active
Location: 7 locations
Glofitamab-based Treatment in Older Adults with Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma or Transformed Lymphoma, GLORY Trial
Status: Active
Location: 7 locations
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 7 locations
Ibrutinib with or without Methotrexate, Rituximab, Vincristine, and Procarbazine in Treating Patients with Newly Diagnosed or Refractory/Recurrent Primary or Secondary Central Nervous System Lymphoma
Status: Active
Location: 7 locations
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Status: Active
Location: 5 locations
Rituximab and Epcoritamab for the Treatment of Follicular Lymphoma
Status: Active
Location: 6 locations
Zanubrutinib, Bendamustine, and Rituximab for the Treatment of Previously Untreated Waldenstrom Macroglobulinemia, ZEBRA Trial
Status: Active
Location: 5 locations
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Status: Active
Location: 5 locations